GSK-49653/347



A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin
rosiglitazone
49653/347
NCT00329225
Diabetes Mellitus, Type 2
Phase 4
 
An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.
September 2013